Cyclooxygenase inhibitors attenuate bradykinin-induced vasoconstriction in septic isolated rat lungs

Anesthesia and Analgesia

Volumn 90, Issue 3, 2000, Pages 625-631

  Fischer, Lars G ^a   Hollmann, Markus W ^a   Horstman, Damian J ^a   Rich, George F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ[8 LEUCINE 9 DEARGININE]; ICATIBANT; INDOMETACIN; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; ENDOTHELIUM INJURY; HYPOXIC LUNG VASOCONSTRICTION; ISOLATED LUNG; LUNG ARTERY PRESSURE; LUNG MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; SEPSIS;

EID: 0034005938     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200003000-00023     Document Type: Article

References (25)

1. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 1998;355: 211-7.
2. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
3. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
4. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47(1):55-9.
5. Fischer LG, Horstman DJ, Hahnenkamp K, et al. Selective iNOS-inhibition attenuates acetylcholine and bradykinin-induced vasoconstriction in lipopolysaccharide-exposed rat lungs. Anesthesiology 1999;91:1724-32.
6. Fasciolo JC, Vargas L, Lama MC, et al. Bradykinin-induced vasoconstriction of rat mesenteric arteries precontracted with noradrenaline. Br J Pharmacol 1990;101:344-8.
7. Yu H, Carretero OA, Juncos LA, et al. Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension 1998;32:287-92.
8. Frank DU, Lowson SM, Roos CM, et al. Endotoxin alters hypoxic pulmonary vasoconstriction in isolated rat lungs. J Appl Physiol 1996;81:1316-22.
9. Marsault R, Illiano S, Vanhoutte PM. Bradykinin-induced contractions of canine saphenous veins: mediation by B2 receptors and involvement of eicosanoids. Br J Pharmacol 1997;120: 215-20.
10. Pruneau D, Luccarini JM, Robert C, et al. Induction of kinin B1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery. Br J Pharmacol 1994;111: 1029-34.
11. Stewart TE, Valenza F, Ribeiro SP, et al. Increased nitric oxide in exhaled gas as an early marker of lung inflammation in a model of sepsis. Am J Respir Crit Care Med 1995;151:713-8.
12. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 1995;3:2-32.
13. Tetsuka T, Daphna-Iken D, Srivastava SK, et al. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci USA 1994;91:12168-72.
14. Voelkel NF, Czartolomna J, Simpson J, et al. FMLP causes eicosanoid-dependent vasoconstriction and edema in lungs from endotoxin-primed rats. Am Rev Respir Dis 1992;145: 701-11.
15. Ogletree ML, Begley CJ, King GA, et al. Influence of steroidal and nonsteroidal anti-inflammatory agents on the accumulation of arachidonic acid metabolites in plasma and lung lymph after endotoxemia in awake sheep: measurements of prostacyclin and thromboxane metabolites and 12-HETE. Am Rev Respir Dis 1986;133:55-61.
16. Heller H, Hoffmann G, Schobersberger W, et al. Effect of inhaled nitric oxide on endotoxin-induced hypoxaemia in rabbits. Acta Physiol Scand 1997;161:311-5.
17. Wanecek M, Rudehill A, Hemsen A, et al. The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit Care Med 1997;25:848-57.
18. Wheeler AP, Hardie WD, Bernard GR. The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep. Am Rev Respir Dis 1992;145:632-9.
19. Briner VA, Tsai P, Schrier RW. Bradykinin: potential for vascular constriction in the presence of endothelial injury. Am J Physiol 1993;264:F322-7.
20. Meyrick BO, Ryan US, Brigham KL. Direct effects of E coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of intimai explants. Am J Pathol 1986;122:140-51.
21. Cao C, Matsumura K, Ozaki M, et al. Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J Neurosci 1999; 19:716-25.
22. Campos MM, Henriques MG, Calixto JB. The role of B1 and B2 kinin receptors in oedema formation after long-term treatment with Mycobacterium bovis bacillus Calmette-Guerin (BCG). Br J Pharmacol 1997;120(3):502-8.
23. Ueno A, Tokumasu T, Naraba H, et al. Involvement of bradykinin in endotoxin-induced vascular permeability increase in the skin of rats. Eur J Pharmacol 1995;284: 211-4.
24. Ahluwalia A, Giuliani S, Scotland R, et al. Ovalbumin-induced neurogenic inflammation in the bladder of sensitized rats. Br J Pharmacol 1998;124:190-6.
25. Nakamura F, Minshall RD, Le Breton GC, et al. Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension 1996;28: 444-9.